FierceBiotechOriginal article
{"a":[{"_":"GSK doubles down on Chimagen with $750M multiple myeloma wager","$":{"href":"/biotech/gsk-doubles-down-chimagen-750m-multiple-myeloma-wager","hreflang":"en"}}]}
PartnershipPositive
AI Analysis
Summary
GSK entered into a partnership with Chimagen Biosciences with up to $750 million in potential payments for a trispecific T-cell engager targeting multiple myeloma, with Phase 1 development expected to commence in 2027.
Clinical Trial Data
Phase
Phase 1
Outcome Details
GSK entered into a deal with Chimagen Biosciences with potential payments up to $750 million for a trispecific T-cell engager for multiple myeloma, with Phase 1 development expected to start in 2027
Importance:7/10
Sentiment:
0.60
partnershipmultiple myelomatrispecific T-cell engagerGSKChimagenphase 1
Read the original article
Published by FierceBiotech on September 15, 2026 6:21 AM